Allurion Technologies Inc. (ALUR) Returns to France with 12.2% Weight Loss, 6.6% Muscle Gain Results
15 States with the Best Healthcare in the US
The study evaluated 1,962 French patients using Allurion Technologies Inc. (NYSE:ALUR)'s Program, which features a swallowable gastric balloon and AI-powered health coaching. Over just four months, participants achieved an average 12.2% reduction in total body weight. Notably, muscle mass as a percentage of body weight increased by 6.6%, and lean body mass rose by 6.0%. Fat mass and visceral fat index dropped by 11% and 12.2%, respectively. These results suggest significant improvements in metabolic health.
Dr. Thibaut Coste, a leading bariatric surgeon, highlighted the importance of losing weight while increasing muscle mass for sustainable, long-term health benefits. Dr. Shantanu Gaur, Allurion Technologies Inc. (NYSE:ALUR)'s Founder and CEO, expressed enthusiasm about returning to the French market, emphasizing the company's commitment to metabolically healthy weight loss and the potential for continued success in France.
While we acknowledge the potential of ALUR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ALUR and that has 100x upside potential, check out our report about this
READ NEXT: and
Disclosure: None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
7 minutes ago
- Bloomberg
Commonwealth Bank Reverses Job Cuts Decision Over AI Chatbots
Commonwealth Bank of Australia reversed a decision to cut 45 customer service roles due to new artificial intelligence technology after pressure from the country's main financial services union. The union took CBA to the workplace relations tribunal earlier this month as the company wasn't being transparent about call volumes, according to a statement Thursday from the Finance Sector Union. The nation's largest lender had said that the voice bot reduced call volumes by 2,000 a week, when union members said volumes were in fact rising and CBA had to offer staff overtime and direct team leaders to answer calls, the union said.
Yahoo
23 minutes ago
- Yahoo
Merck & Co., Inc. (MRK) Announces Update on Phase 3 KEYNOTE-905 Trial
Merck & Co., Inc. (NYSE:MRK) is included in our list of the . A dose bottle of the medication is in the medical tech's hand On August 12, 2025, Merck & Co., Inc. (NYSE:MRK) announced an update regarding its Phase 3 KEYNOTE-905 trial. According to the update, the trial met its primary and key secondary endpoints in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy. The study revealed improved event-free survival, overall survival, and pathologic complete response rates compared to surgery alone. The improved outcome was a result of giving patients KEYTRUDA (pembrolizumab) and Padcev (enfortumab vedotin-ejfv) medicines before and after surgery. The trial, carried out in collaboration with Pfizer and Astellas, marks the first systemic treatment that enhances survival rates in this patient group. Furthermore, no new side effects were observed. Operating through its Pharmaceutical and Animal Health segments, Merck & Co., Inc. (NYSE:MRK) leads as a healthcare company worldwide. It is included in our list of the most undervalued value stocks to buy. While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Oil Refinery Stocks to Buy Right Now and 7 Best Potash Stocks to Buy According to Analysts. Disclosure: None.
Yahoo
34 minutes ago
- Yahoo
Beijing turns against Nvidia's AI chip after ‘insulting' Lutnick remarks
Beijing's move to restrict sales of Nvidia's China-specific artificial intelligence processor was prompted by remarks from US commerce Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
